AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. With the amendments, claims remain pending.

Listing of Claims:

1.-44. (Cancelled)

45. (Original) A method for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to expression of a gene regulated by NF-κB, comprising the step of:

a) administration of a composition comprising an NF-κB decoy and a pharmaceutically acceptable carrier to the respiratory system of a subject.

46. (Original) A method according to claim 45, wherein said disease, disorder and/or condition of the respiratory system is airway inflammatory disease, airway stenosis or nasal cavity inflammatory disease.

47. (Original) A method according to claim 45, wherein said disease, disorder and/or condition of respiratory system is COPD, asthma or rhinitis.

48. (Original) A method according to claim 45, wherein said administration to the respiratory system comprises administration into the airway, the lung, transairway absorption or nasal absorption.

49. (Original) A method according to claim 45, wherein said administration to the respiratory system is administration to the airway by

atomization or inspiration.

50. (Original) A method according to claim 45, wherein said administration Into the airway comprises administration by metered dose inhaler (MDI), dry powder Inhaler (DPI) or nebulizer,

51. (Original) A method according to claim 45, wherein administration is achieved by means selected from the group consisting of a nasal drop, a nasal spray, a nebulizer, a respirator and powder administration.

52. (Original) A method for treating and/or preventing a disease, disorder and/or condition of the respiratory system due to an eosinophil abnormality, comprising the step of:

a) administration of a composition comprising an NF-κB decoy and a pharmaceutical acceptable carrier to the respiratory system of a subject.

53.-54. (Cancelled)

55. (New) A method according to claim 45, wherein said NP-kB decoy is a NP-kB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment has a biological activity.

56. (New) A method according to claim 45, wherein said NF-kB decoy is a decoy set forth in SEQ. ID NO: 1.

57. (New) A method according to claim 45, wherein said pharmaceutically acceptable carrier is a hydrophilic polymer, a carbohydrate or an

insoluble additive.

58. (New) A method according to claim 45, wherein said pharmaceutically acceptable carrier is at least one type selected from the group consisting of a liposome, lactose, trehalose, sucrose, mannitol and xylitol.

59. (New) A method according to claim 52, wherein said NF-kB decoy is a NP-kb decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment has a biological activity.

60. (New) A method according to claim 52, wherein said NP-kB decoy is a decoy set forth in SEQ. ID NO: 1.

61. (New) A method according to claim 52 wherein said disease, disorder and/or condition of respiratory system is airway inflammatory disease, airway stenosis or nasal cavity inflammatory disease.

62. (New) A method according to claim 52, wherein said disease, disorder and/or condition of the respiratory system Is COPD, asthma or rhinitis.

63. (New) A method according to claim 52, wherein said pharmaceutically acceptable carrier is a hydrophilic polymer, a carbohydrate or an insoluble additive.

64. (New) A method according to claim 52, wherein said pharmaceutically acceptable carrier is at least one type selected from the group consisting of a liposome, lactose, trehalose, sucrose, mannitol and xylitol.

65. (New) A method according to claim 52, wherein said administration to the respiratory system comprises administration into the airway, the lung, transairway absorption or nasal absorption.

66. (New) A method according to claim 52, wherein said administration to the respiratory system is administration to the airway by atomization or inspiration.

67. (New) A method according to claim 52, wherein said administration into the airway comprises administration by metered dose inhaler (MDI), dry powder inhaler (DPI) or nebulizer.

68. (New) A method according to claim 50, wherein said composition is provided as a dry powder.

69. (New) A method according to claim 68, wherein the dry powder has an aerodynamic average particle size of about 0.01 to about 50 micrometer.

70. (New) A method according to claim 68, wherein the dry powder has an aerodynamic average particle size of about 0.05 to about 30 micrometer.

71. (New) A method according to claim 68, wherein the dry powder has an aerodynamic average particle size of about 0,1 to about 10 micrometer.

72. (New) A method according to claim 67, wherein said composition is provided as a dry powder.

73. (New) A method according to claim 72, wherein the dry powder has an aerodynamic average particle size of about 0.01 to about 50 micrometer.

74. (New) A method according to claim 72, wherein the dry powder has an aerodynamic average particle size of about 0.05 to about 30 micrometer.

75. (New) A method according to claim 72, wherein the dry powder has an aerodynamic average particle size of about 0.1 to about 10 micrometer.

76. (New) A method according to claim 45, wherein a dosage of 10 mg to 100 mg per round is provided.

77. (New) A method according to claim 52, wherein a dosage of 10 mg to 100 mg per round is provided.

78. (New) A method according to claim 45, wherein the administration to the respiratory system comprises nasal absorption.

79. (New) A method according to claim 78, which is a formulation selected from the group consisting of a nasal drop, a nasal spray agent, an agent for nebulizer, an agent for a respirator and powder administration

formulation.

80. (New) A method according to claim 78, which is a nasal drop for rhinitis.

81. (New) A method according to claim 52, wherein the administration to the respiratory system comprises nasal absorption.

82. (New) A method according to claim 81, which is a formulation selected from the group consisting of a nasal drop, a nasal spray agent, an agent for nebulizer, an agent for a respirator and powder administration formulation.

83. (New) A method according to claim 81, which Is a nasal drop for rhinitis.

84. (New) A method according to claim 45, wherein the NF-kB decoy is encapsulated in an HVJ-E envelope vector.

85. (New) A method according to claim 52, wherein the NF-kB decoy is encapsulated in an HVJ-E envelope vector.